GPGrossPatternRESEARCH SYSTEM
SEC CHECK OPERATIONAL
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

BTAI · Mar 31, 2025

BioXcel Therapeutics, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration

State dimensions

Filing0001558370-25-007269General Corporate
Debt relative to revenueRAWCurrent state valid · history insufficient
Evidence method

Level · gp.fundamentals.debt_to_revenue

62813.10% · OPTIONAL · NOT_ENOUGH_HISTORY

Operating cash generation70thOwn-history percentile · N=10
Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

-7168.45% · OPTIONAL · VALID

Revenue growthRAWCurrent state valid · history insufficient
Evidence method

Yoy · gp.fundamentals.revenue

-71.13% · CORE · NOT_ENOUGH_HISTORY

Inventory pressure30thOwn-history percentile · N=10
Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

382.14% · OPTIONAL · VALID

Gross margin50thOwn-history percentile · N=10
Evidence method

Level · gp.fundamentals.gross_margin

91.67% · CORE · VALID

Operating margin70thOwn-history percentile · N=10
Evidence method

Level · gp.fundamentals.operating_margin

-6011.31% · CORE · VALID

R&D intensity40thOwn-history percentile · N=10
Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

2710.71% · OPTIONAL · VALID

SBC intensity10thOwn-history percentile · N=10
Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

107.14% · OPTIONAL · VALID

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History16 statesHistory building
Sep 30, 20220/7 normalizedLevel 3Dec 31, 20220/7 normalizedLevel 3Mar 31, 20230/6 normalizedLevel 3Jun 30, 20230/6 normalizedLevel 3Sep 30, 20230/8 normalizedLevel 3Dec 31, 20230/8 normalizedLevel 3Mar 31, 20240/7 normalizedLevel 3Jun 30, 20240/7 normalizedLevel 3Sep 30, 20246/7 normalizedLevel 3Dec 31, 20246/7 normalizedLevel 3Mar 31, 20256/8 normalizedLevel 3Jun 30, 20256/8 normalizedLevel 3Sep 30, 20257/9 normalizedLevel 3Dec 31, 20257/9 normalizedLevel 3Mar 31, 20267/9 normalizedLevel 3Jun 30, 20267/9 normalizedLevel 3
Period transition

What moved in the state?

Cash Generation Decreased
Previous
-3178.60%
Current
-7168.45%
Delta
-3989.86%
Growth Decreased
Previous
64.20%
Current
-71.13%
Delta
-135.34%
Inventory Pressure Increased
Previous
29.96%
Current
382.14%
Delta
352.18%
Margin Increased
Previous
5.43%
Current
91.67%
Delta
86.24%
Profitability Decreased
Previous
-2967.56%
Current
-6011.31%
Delta
-3043.75%
R And D Intensity Increased
Previous
1343.12%
Current
2710.71%
Delta
1367.60%
Sbc Intensity Decreased
Previous
271.67%
Current
107.14%
Delta
-164.53%
Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.
Research Graph

Related governed research

Transitioned To · BTAI Fundamental State →Transitioned To · BTAI Fundamental State →Transitioned To · BTAI CASH_GENERATION_DECREASED →Transitioned To · BTAI GROWTH_DECREASED →Transitioned To · BTAI INVENTORY_PRESSURE_INCREASED →Transitioned To · BTAI MARGIN_INCREASED →Transitioned To · BTAI PROFITABILITY_DECREASED →Transitioned To · BTAI R_AND_D_INTENSITY_INCREASED →Transitioned To · BTAI SBC_INTENSITY_DECREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.